This study reviewed the efficacy/effectiveness, immunogenicity, and safety profile of the 12 most progressed COVID-19 vaccines and discussed the challenges and prospects of the vaccine-based approaches in a global crisis. Overall, most of the current vaccines have shown safety and efficacy/...
A recent study conducted by Public Health England found that the available vaccines were “highly effective” at preventing hospitalization after two doses.
Emergency use authorization of COVID vaccines has brought hope to mitigate pandemic of coronavirus disease 2019 (COVID-19). However, there remains a need for additional effective vaccines to meet the global demand and address the potential new viral variants. mRNA technologies offer an expeditious ...
Pharmacological Reports (2022) 74:1228–1237 https://doi.org/10.1007/s43440-022-00429-1 SPECIAL ISSUE: REVIEW The Post-COVID Era - Advances and Challenges in Pharmacology Efficacy of COVID‑19 vaccines: a systematic review and network meta‑analysis of phase 3 randomized ...
The 2024-2025 vaccine recommendations bring several key updates across multiple vaccines. For influenza, the universal recommendation remains for everyone 6 months and older, with preferential high-dose vaccines for those 65 and over. COVID-19 vaccination is univer...
We estimated the average protection against both symptomatic and severe COVID-19 provided by the different boosters over a 6-month period, assuming antibody titers decay at the same rate for both vaccines (with a half-life of 108 days15,17,19). The relative benefits of a variant-modified...
The variant, known as B.1.351, carries mutations that threaten the efficacy of COVID-19 vaccines, several studies have shown. Most vaccine makers, including Novavax, are testing versions of their vaccines to protect against emerging variants. The Novavax post-hoc analysis was...
Wu et al. BMC Infectious Diseases (2024) 24:234 https://doi.org/10.1186/s12879-023-08754-3 BMC Infectious Diseases RESEARCH Open Access Comparative efficacy and safety of COVID-19 vaccines in phase III trials: a network meta- analysis Xiaodi Wu1†, Ke Xu1†, Ping Zhan2, ...
as well as real-world data on vaccine effectiveness and the impact of virus variants of concern. Where they have been deployed in a high proportion of the adult population, the currently approved vaccines have been extremely effective in preventing COVID-19, particularly severe disease. Nonetheless...
[35]. This enzymatic activity leads to the release of viral genome content into the host cell by viral membrane fusion, while infection with SARS-CoV-2 is also reported to enhance CTSL gene expression [36]; thus, targeting this pathway might confer new insights into the treatment of COVID-...